Skip to main content
. 2022 Jan 18;6:4. doi: 10.1038/s41698-021-00243-7

Fig. 2. Performances of the three models in the training sets of nonsquamous NSCLC.

Fig. 2

A Workflow of developing and validating three models in nonsquamous NSCLC. B, C The single mutations (B) and interaction effects of co-mutations (C) selected for model development. D Calibration curves of the three models in the training sets-1/2. E Youden’s index based on the receiver operating characteristic curve of the three inter-scores and response to anti-PD-(L)1 monotherapy in the training sets-1/2. F Performances of the three models on discriminating the PFS and OS on anti-PD-(L)1 monotherapy in the training sets-1/2. G Performances of the three models on predicting the PFS and OS benefit from atezolizumab over docetaxel in the POPLAR/OAK cohort. Abbreviations: DFCI Dana Farber Cancer Institute, MSKCC Memorial Sloan-Kettering Cancer Center, NSCLC nonsmall cell lung cancer, OS overall survival, PD-1 programmed death-1, PD-L1 programmed death-ligand 1, PFS progression-free survival, SYSUCC Sun Yat-Sen University Cancer Center.